Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ublituximab SC PK and Safety in Multiple Sclerosis
NCT07503873Phase 2Recruiting
- Sponsor
- TG Therapeutics, Inc.
- Start
- Apr 2026
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 2, randomised trial of ublituximab in multiple sclerosis (MS) (2 arms), sponsored by TG Therapeutics, Inc. Primary endpoint: Area under the curve at Steady State of Ublituximab at 12 weeks. Started Apr 2026; status: recruiting.
02
Drugs
ublituximab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT07503873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07503873.